Hyperbaric oxygenation induced tolerance against focal cerebral ischemia in mice is strain dependent

SV129 or C57BL/6 mice were exposed to hyperbaric oxygenation (HBO, 5 days, 1 h every day, 100% O(2) at 3 atm absolute). One day after the 5th HBO session focal cerebral ischemia was induced. In SV129 mice, HBO induced tolerance against permanent focal cerebral ischemia (n=42, mean infarct volume reduction 27%, P=0.001), but not against transient (30 or 60 min) focal cerebral ischemia. In the C57BL/6 strain of mice, HBO did not induce tolerance against focal cerebral ischemia, even when the duration of ischemia or the HBO protocol were modified. For the first time we demonstrate that HBO can induce tolerance to focal cerebral ischemia, but this effect is strain dependent.     

硬膜外麻醉复合全麻对开胸手术患者早期恢复质量的影响

目的 探讨硬膜外腔阻滞复合全麻与肋间神经阻滞复合全麻对开胸手术患者早期恢复质量的影响。方法 选取行开胸手术患者76例,按随机数表法分为两组,硬膜外阻滞复合全麻组（E组）、肋间神经阻滞复合全麻组（C组）,每组38例。E组行硬膜外穿刺置管,术中0.2%罗哌卡因维持;C组行切口及上下肋间神经阻滞,两组全麻诱导及维持一致。采用术后恢复质量量表(quality of recovery QoR-40）对患者进行术前1d、术后3d恢复质量评分;采用视觉模拟评分法（visual analogue scale, VAS）对两组患者进行拔管后4 h、8 h、12 h、24 h安静和活动后的VAS评分;同时记录患者首次下床活动时间及住院时间。结果 E组在术后3dQoR-40各项评分均高于C组,差异有统计学意义（P <0.05）;E组静息和运动状态下术后各时间点VAS评分均低于C组,差异有统计学意义（P <0.05）;E组首次下床活动时间较早,住院时间较C组减少,差异有统计学意义（P <0.05）。结论 硬膜外阻滞复合全身麻醉用于开胸手术患者,不仅镇痛效果良好,还能明显提高术后早期恢复质量,...     

超早产儿/超低出生体重儿临床结局的性别差异：一项倾向性评分匹配研究

目的通过倾向性评分匹配方法，探讨性别对超早产儿/超低出生体重儿（extremely preterm infant/extremely low birth weight infant，EPI/ELBWI）临床结局的影响。方法回顾性分析2011年1月1日至2020年12月31日住院的731例EPI或ELBWI的临床资料，将731例EPI/ELBWI分成男婴组与女婴组。通过倾向性评分匹配方法1∶1匹配，匹配变量包括：胎龄、出生体重、放弃积极治疗比例、小于胎龄儿比例、使用肺表面活性物质比例、1 min Apgar评分≤3分比例、机械通气比例、机械通气时间、产前使用疗程不足糖皮质激素比例和妊娠期高血压疾病比例，比较两组患儿住院期间主要并发症的发生率和出院存活率。结果匹配前，男婴组新生儿呼吸窘迫综合征、支气管肺发育不良、重度脑室内出血、脑室周围白质软化、坏死性小肠结肠炎、动脉导管未闭的发生率均显著高于女婴组（P<0.05）；匹配后，男婴组仅支气管肺发育不良的发生率显著高于女婴组（P<0.05）。匹配前后，两组患儿的出院存活率差异均无统计学意义（P>0.05）。结论男婴EPI/ELBWI并发支气管肺发育不良的风险高于女婴，但男婴和女婴EPI/ELBWI的转归相似。     

Effect of Clopidogrel on Platelet Membrane CD40 Ligand in Coronary Artery Disease Patients Undertaking Percutaneous Coronary Intervention

Objectives To investigate the change and clinical significance of clopidogrel on platelet membrane CD40L in coronary artery disease patients before and after percutaneous coronary intervention(PCI). Methods 30 cases who were diagnosis coronary artery diseases(CAD) by coronary angiography, mean age 56±9 years old. All the patients who had no antiplatelet aggregation contraindication, were treated with standard anti angina pectoris drugs. Before PCI, all the patients took clopidogrel 75 mg per day. Activated platelet membrane CD40L express rate was measured by flow cytometry before and after PCI 6 hours. Results Activated platelet membrane CD40L express rate were 3.73±2.15 and 2.46±0.90, respectively in 30 patients before and after PCI 6 hours. Activated platelet membrane CD40L express rate was significantly decrease after PCI 6 hours than that before PCI(P<0.01). Conclusions Clopidogrel has significance effect on platelet membrane CD40L in coronary artery disease patients undergoing PCI. Clopidogrel can suppression platelet activation and prevent thromboembolism event occurrence.     

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers

In order to stimulate antigen presentation and T cell activity against cancer, we treated three different tumor models in mice with the monoclonal antibodies anti-CD40 plus anti-CD137 (BiMab). In a subcutaneous transplantable MC38 colon cancer model, there was significant enhancement in the survival of mice following BiMab treatment. Anti-CD40 has shown considerable success against lymphoma in previous studies by other investigators, and we also showed in this study that, in a model of Eμ-Myc lymphoma, there was a statistically significant enhancement of survival of mice following BiMab treatment. Following the success of the BiMab treatment in the previous two models, we wished to determine if it would be successful in a mouse model of multiple myeloma. Firstly, we tested a transplantable model of disease in which multiple myeloma cells derived from Vk*MYC mice were injected intravenously. A minor proportion of anti-CD137 and BiMab treated mice experienced prolongation of life beyond 250 days. Then we tested the therapy in a spontaneously occurring multiple myeloma model, in Vk*MYC transgenic mice. The majority of mice treated survived longer than control mice, although statistical significance was not demonstrated.     

急性肺栓塞患者BNP、CTnI、D-dimer水平改变及其临床意义

【目的】探讨检测急性肺栓塞患者的血浆脑钠肽（BNP）、肌钙蛋白I（cTnI）及D‐二聚体（D‐dimer）水平变化的临床意义。【方法】选择本院2009年1月至2013年12月收治的急性肺栓塞患者64例,根据患者病情分为大面积肺栓塞组（ n ＝27）和非大面积肺栓塞组（ n ＝37）,对两组患者血浆cTnI、BNP及D‐dimer水平进行测定,观察比较两组患者各指标水平的变化及右心功能和病死率。【结果】大面积肺栓塞组BN P、血浆cTnI水平明显高于非大面积肺栓塞组,两组比较差异有显著性（ P ＜0．05）;两组D‐dimer浓度比较差异无统计学意义（ P ＞0．05）;大面积肺栓塞组的右心功能不全者和病死率均高于非大面积肺栓塞组,两组比较差异有统计学意义（ P ＜0．05）。【结论】检测BNP、cTnI及D‐dimer水平对APE患者临床诊断、临床决策及预后判断具有重要的临床意义。     

乙酰紫草素注射液对小鼠Lewis肺癌生长抑制的研究

目的:探讨乙酰紫草素注射液对小鼠Lewis肺癌的生长抑制作用。方法:建立C57BL/6小鼠lewis肺癌模型进行体内抗瘤实验并计算抑瘤率。结果:乙酰紫草素注射液高中低剂量组的抑瘤率分别为55.49%,45.25%和28.09%。结论:乙酰紫草素注射液能明显抑制小鼠Lewis肺癌的生长。     

心脏性猝死病人心肌组织CX43和CX40的表达

目的观察心脏性猝死病人左、右心室肌及室间隔肌缝隙连接蛋白43(CX43)及缝隙连接蛋白40(CX40)的表达,探讨CX43、CX40表达与心脏性猝死的关系。方法应用免疫组化及Simple PCI图像分析系统,分析比较心脏性猝死与非心脏性猝死病人心室肌及室间隔肌CX43、CX40的表达,并用SPSS 13.0统计软件对数据进行统计分析。结果非心脏性猝死病人CX43、CX40主要表达于心肌细胞闰盘处,少数表达于细胞侧面连接及胞浆中。心脏性猝死病人CX43、CX40多数弥散于胞浆及细胞侧面连接处,表达于闰盘的数量减少。心脏性猝死病人CX43在左心室、室间隔及右心室的表达明显低于对照组(t=2.09~8.01,P均<0.05);心脏性猝死病人CX40在左心室、室间隔及右心室的表达也明显低于对照组(t=3.24~9.40,P均<0.05)。结论CX43、CX40表达部位的改变与表达数量的减少,可能与心脏性猝死有一定关系。     

Umbilical cord stem cell transplantation for primary immunodeficiencies

Primary immunodeficiencies (PIDs) are a rare but important cause of mortality and morbidity in childhood: the most severe – known as severe combined immunodeficiency (SCID) – are fatal within the first year of life; other PIDs are less immediately life-threatening, but have a poor long-term outlook. Haematopoietic stem cell transplantation (HSCT) is the best treatment for SCID and is increasingly offered for other PIDs. The best results are achieved with an HLA-matched family donor. Umbilical cord stem cells (UCSCs) are an alternative stem cell source. Results using UCSCs in the treatment of haematological disorders and malignancy are as good as those for which marrow is the stem cell source. Although PIDs make up a small proportion of disorders amenable to treatment by HSCT, UCSCs are an ideal source of haematopoietic stem cells for many of these patients. Of the 52 patients with SCID or other PIDs for whom detailed information on outcome is available, results of engraftment, immune reconstitution, incidence of graft-versus-host disease and survival are comparable with other stem cell sources. Small stem cell dose and prolonged time to viral immunity limit the patients for whom UCSCs can be used. Newer methods of achieving better engraftment, ex vivo expansion of stem cells and generation of antigen-specific cytotoxic T cells are being developed at present, and will widen the application of UCSCs as a viable source for more patients.